Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: May 14, 2009


Title: Lipids for Transfection of Nucleic Acids

Number: 7,531,693

Filed: May 24, 2004

Lead Inventor: Gulilat Gebeyehu, Molecular Transfer

The patent, its abstract states, claims "cationic lipid compositions … that are useful for efficient delivery of macromolecules, such as nucleic acids, into a wide variety of eukaryotic cell types," as well as methods for using the compositions.

Title: Topical Administration of at Least One Double-Stranded RNA Oligonucleotide

Number: 20090117063

Filed: Jan. 9, 2008

Lead Inventor: Albert Duranton, L'Oreal

"Expression of a messenger RNA which encodes a protein which is expressed by differentiated cells, notably the cells of the skin or appendages thereof, is inhibited by topically administering to said differentiated cells a thus effective amount of at least one double-stranded RNA oligonucleotide, formulated into a topically applicable, physiologically acceptable medium therefore," the patent application's abstract states. "Such regime or regimen is useful for treating a variety of afflictions or conditions, e.g., combating the signs of skin aging, stimulating hair growth or retarding loss thereof, inhibiting cellular proliferation and/or differentiation, etc."

Title: DNA Sequences for Gene Suppression

Number: 20090117539

Filed: April 5, 2006

Lead Inventor: Larry Gilbertson, Monsanto

The invention, the patent application's abstract states, comprises "methods of improving DNA sequences for gene suppression mediated by double-stranded RNA, and constructs and transgenic organisms containing such improved DNA sequences."

Title: Macrophage Transfection Method

Number: 20090117658

Filed: April 25, 2008

Lead Inventor: Thomas Wagner, Greenville Hospital System

The patent application, its abstract states, claims "a method and a composition for transfecting monocytes, as well as use of the same for therapeutic purposes. The composition is composed of a nucleic acid component, a lysosome-evading component, and a digestible particle that can be phagocytized. Preferably, the monocyte is a macrophage and the digestible particle is from a natural source, such as from a microbial source. More preferably, the digestible particle is a yeast cell wall particle such as zymosan," the abstract notes.

"The composition itself, or cells pretreated with the composition, are useful in all gene-medicine applications, such as gene therapy, gene vaccination, cancer treatment, as well as immunomodulation and tissue repair," it adds.

[ pagebreak ]

Title: RNA Interference for the Treatment of Gain-of-Function Disorders

Number: 20090118206

Filed: Sept. 13, 2004 PCT Filed: Sept. 13, 2004

Lead Inventor: Neil Aronin, University of Massachusetts Medical School

The invention, according to the patent application's abstract, "relates to the discovery of an effective treatment for a variety of gain-of-function diseases, in particular, Huntington's disease. The present invention utilizes RNA interference technology against polymorphic regions in the genes encoding various gain-of-function mutant proteins resulting in an effective treatment for the gain-of-function disease."

Title: Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases

Number: 20090118208

Filed: June 29, 2007

Lead Inventor: Yijia Liu, Intradigm

The patent application, its abstract states, claims "compositions and methods … for treatment of diseases involving unwanted neovascularization. The invention provides treatments that control [neovascularization] through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological [neovascularization] tissues."

The abstract adds that the application further claims "tissue-targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference. ... The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists … [and] the compositions and methods can be used for the treatment of [neovascularization] diseases such as cancer, ocular disease, arthritis, and inflammatory diseases."

Title: Composition for Conferring Tolerance to Viral Disease in Social Insects and the Use Thereof

Number: 20090118214

Filed: Aug. 20, 2008

Lead Inventor:
Nitzan Paldi, Beeologics

The patent application, its abstract states, claims "compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus by feeding of pathogen-specific dsRNA." The application also claims multiple pathogen-specific dsRNA.

Title: siRNA Targeting Nucleoporin 62kDa

Number: 20090118489

Filed: June 9, 2008

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for Nup62."\

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.